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Background information. CtBPs [C-terminal (of E1A) binding protein] have roles in the nucleus as transcriptional
co-repressors, and in the cytoplasm in the maintenance of vesicular membranes. CtBPs are expressed from two
genes, CTBP1 and CTBP2, mRNA products of which are alternatively spliced at their 5 -ends to generate distinct
protein isoforms. Extensive molecular and cellular analyses have identiﬁed CtBPs as regulators of pathways critical
for tumour initiation, progression and response to therapy. However, little is known of the expression or regulation
of CtBP isoforms in human cancer, nor of the relative contributions of CTBP1 and CTBP2 to the tumour cell
phenotype.
Results. Expression of CtBP proteins and CTBP1 and CTBP2 mRNA splice forms in breast cancer cell lines and
tumour tissue was examined. CtBP1 proteins are identiﬁable as a single band on Western blots and are ubiquitously
detectable in breast tumour samples, by both Western blotting and immunohistochemistry. CtBP1 is present in
six of six breast cancer cell lines, although it is barely detectable in SKBr3 cells due to reduced CTBP1 mRNA
expression. In the cell lines, the predominant CTBP1 mRNA splice form encodes CtBP1-S protein; in tumours,
both major CTBP1 mRNA splice forms are variably expressed. CtBP2 proteins are ubiquitously expressed in all
lines and tumour samples. The predominant CTBP2 mRNA encodes CtBP2-L, although an alternatively spliced
form that encodes CtBP2-S, previously unidentiﬁed in humans, is expressed at low abundance. Both CtBP2-L and
CtBP2-S are readily detectable as two distinct bands on Western blots; here we show that the CTBP2-L mRNA is
translated from two AUG codons to generate both CtBP2-L and CtBP2-S. We have also identiﬁed an autoregulatory
feedback mechanism whereby CtBP protein abundance is maintained in proliferating breast cancer cells through
the post-transcriptional regulation of CtBP2. This feedback is disrupted by UV-C radiation or exposure to cisplatin.
Finally, we demonstrate that CtBP1 and CtBP2 both have p53-dependent and -independent roles in suppressing
the sensitivity of breast cancer cells to mechanistically diverse cancer chemotherapeutic agents.
Conclusions. These studies support recent evidence that CtBP family proteins represent potential targets for
therapeutic strategies for the treatment of cancer in general, and breast cancer in particular.
1To whom correspondence should be addressed (email
j.p.blaydes@soton.ac.uk).
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Abbreviations used: APC, adenomatous polyposis coli; ARF, alternative
reading frame; BARS, Brefeldin A ADP-ribosylated substrate; BH3 domain,
Bcl-2 homology domain 3; CtBP, C-terminal (of E1A) binding protein; DAPI,
4 ,6-diamidino-2-phenylindole; HEK-293 cells, human embryonic kidney cells;
HIPK2, homeodomain-interacting protein kinase 2; MTS, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium; RT−PCR, reverse transcription−PCR; siRNA, small interfering
RNA.
Introduction
The oncogenic CtBPs [C-terminal (of E1A) binding
protein] were discovered through their interaction
with the C-terminus of the E1A protein from aden-
ovirus (Boyd et al., 1993). They have since begun to
generate interest as potential therapeutic targets for
thetreatmentofcancer(BergmanandBlaydes,2006;
Chinnadurai, 2009). Invertebrates such as Drosophila
possess one CtBP-encoding locus (dCtBP), whereas
vertebrate species possess two loci: CTBP1 and
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CTBP2 (Chinnadurai, 2002; Bergman and Blaydes,
2006). In humans these map to chromosomes 4 and
10 respectively. Several homologous proteins are en-
coded by mammalian CtBP-encoding genes: CTBP1
encodes CtBP1-L and CtBP1-S, whereas CTBP2
codes for CtBP2-L, CtBP2-S and RIBEYE (Spano
et al., 1999; Schmitz et al., 2000; Verger et al.,
2006), summarized in Bergman et al. (2006). The
CtBPs are highly conserved between species and the
vertebrate CtBP1 and CtBP2 proteins share 78%
amino acid homology. The two proteins exhibit a
conserved N-terminal amino acid sequence, import-
antinprotein−proteininteractions,andacentralde-
hydrogenasedomainnecessaryforNADH-dependent
dimerization (Chinnadurai, 2002; Nardini et al.,
2003). In animal models the CtBPs have been
shown to be widely expressed during numerous
developmental processes, as well as in adult cells
(Chinnadurai, 2002; Hildebrand and Soriano,
2002). Indeed homozygous knockout Drosophila
(dCtBP−/−) exhibit lethal phenotypic abnormalit-
ies (Poortinga et al., 1998). Similar effects have been
demonstrated in mouse embryo models (Hildebrand
and Soriano, 2002): ctbp1−/− animals are small and
have a signiﬁcantly shorter life expectancy, whereas
ctbp2−/− embryosdieinutero.Inaddition,thephen-
otypicdefectsseenintheneurological,cardiovascular
and musculoskeletal systems of ctbp2−/− embryos
are worsened if they are also ctbp1−/−, indicating
that the two proteins, despite having distinct roles,
may share considerable functional overlap.
Through their interaction with adenovirus
E1A, the function of CtBPs was identiﬁed as
transcriptional co-repressors (Chinnadurai, 2002).
CtBPs associate with chromatin-modifying enzymes
including histone deacetylases to form a chromatin-
modifying complex, which is recruited to chromatin
viatheassociationofCtBPswithDNA-bindingtran-
scription factors (Shi et al., 2003). Most of these
transcription factors, as well as E1A, are character-
ized by the presence of a consensus CtBP-binding
motif, PxDLS, which associates with the N-terminal
protein-binding domain of CtBPs (Chinnadurai,
2002). Formation of the chromatin-modifying com-
plex is dependent on dimerization of CtBPs, which is
promoted by elevated levels of NADH in the cytosol
and nuclei of cells. Hence, CtBP-dependent tran-
scriptional repression is sensitive to perturbations in
cellular metabolism, such as hypoxia (Zhang et al.,
2002; Fjeld et al., 2003) and increased glycolysis
(Zhang et al., 2007). Interestingly, the interaction of
CtBPs with certain proteins is reduced by NADH,
notably MDM2 (Mirnezami et al., 2003) and the
p300histoneacetyltransferase(Kimetal.,2005),and
hence rather than simply promoting the transcrip-
tional repressor function of CtBPs, NADH binding
may toggle CtBPs between two functional forms in
response to cellular metabolic status. CtBPs function
as co-repressors for a substantial number of transcrip-
tional repressors and consequently regulate diverse
cellular processes. For example, CtBP-regulated
cellular phenotypes of relevance to tumour initiation
and development include epithelial−mesenchymal
transition, apoptosis and cell cycle progression,
migration and invasion, angiogenesis, senescence
and mitotic ﬁdelity (e.g. Chen et al., 2008; Mroz
et al., 2008; Bergman et al., 2009; reviewed in
Bergman and Blaydes, 2006; Chinnadurai, 2009).
Both CtBP1 and CtBP2 have demonstrated
co-repressor activity, indeed the two proteins het-
erodimerize. The more severe phenotype associated
with loss of CtBP2 compared with CtBP1 in some
models (Hildebrand and Soriano, 2002; Paliwal
et al., 2006) may in part be due to the presence
of a nuclear localization sequence in CtBP2-L,
whereas the nuclear localization of CtBP1 proteins
requires that they associate with other molecules
including CtBP2-L (Bergman et al., 2006; Verger
et al., 2006; Zhao et al., 2006). In addition to
their role as transcriptional repressors, CtBPs were
independently identiﬁed as cytoplasmic proteins
withakeyroleintheregulationofGolgiarchitecture
and endocytosis (Gallop et al., 2005; Corda et al.,
2006; Colanzi et al., 2007). To date this activity has
been primarily ascribed to the CtBP1-S form [which
is generally termed CtBP3 or BARS (Brefeldin A
ADP-ribosylated substrate) in this context].
Early experiments indicated a role for CtBPs in
the regulation of cellular transformation: E1A lack-
ing its C-terminal CtBP-interacting domain being
more effective than full-length E1A in promoting
cellular immortalization, as well as metastatic trans-
formation, when in cooperation with mutant RAS
(Boyd et al., 1993). Recently, dysregulated con-
trol of the abundance of CtBP1 has been identi-
ﬁed as a key initiating step in the formation of
colorectal tumours: CtBP degradation is dependent
on APC (adenomatous polyposis coli) in these cells,
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andmutationofAPCleadstoelevatedCtBP1protein
abundance with resultant changes in intestinal cell
fate and differentiation that initiate adenoma form-
ation (Nadauld et al., 2006; Phelps et al., 2009).
Conversely, in melanoma, reduced CtBP1 expression
is correlated with disease progression, due to loss of
CtBP-dependent repression of MIA (melanoma in-
hibitory activity) gene expression in this cell type. A
recentgenome-wideassociationstudyinprostatecan-
cer identiﬁed a single-nucleotide polymorphism in
CTBP2 as highly associated with this tumour type,
although the functional consequences of this poly-
morphism are unknown. In general, however, results
ontheexpressionofCtBPproteinsincancerarerather
limited; its expression in breast cancer has not been
reported, and analysis of the major CtBP protein iso-
forms has not been described in any tumour type.
Inadditiontorolesintheinitiationandprogression
of tumorigenesis, CtBPs have also been implicated
in the cellular responses to anticancer chemothera-
peutic agents. Immortalized mouse embryo ﬁbro-
blasts from ctbp1−/−ctbp2−/− animals proliferate
incultureapparentlynormally,butarehypersensitive
to the topoisomerase II inhibitor, etoposide (Groote-
claes et al., 2003). In addition, certain forms of geno-
toxic agent induce the activity of signalling kinases,
HIPK2 (homeodomain-interacting protein kinase 2)
or JNK1 (c-Jun N-terminal kinase 1), which phos-
phorylate CtBP1-L on Ser-422 (Zhang et al., 2003;
Wang et al., 2006; this site is conserved on CtBP2),
and promote its proteasome-dependent degradation.
This signalling event is a measurable component of
the mechanism of cancer cell killing by cisplatin
(Wang et al., 2006). Full details of the mechan-
ism of this process are yet to be fully characterized;
however, the tumour suppressor p14ARF (ARF is al-
ternative reading frame) has been demonstrated to
be required for stress-induced degradation of CtBP
proteins (Paliwal et al., 2006). Chemo-sensitization
through reduction in CtBP abundance involves an
enhanced apoptotic response, which can be due to
loss of CtBP-dependent repression of BH3 domain
(Bcl-2 homology domain 3)-only protein expression
(Kovietal.,2010).Wehavealsorecentlyshownthat,
in both breast cancer cell lines and non-transformed
human ﬁbroblasts, siRNA (small interfering RNA)-
mediatedknockdownofCtBPproteinexpressionres-
ultsinalossofmitoticﬁdelity;CtBPknockdownalso
induces the activation of a p53-dependent cell cycle
arrest response, which, in cells where this pathway
is functional, suppresses the proapoptotic response to
CtBP loss (Bergman et al., 2009). As other studies of
the CtBP-dependent suppression of chemosensitiv-
ity have focused on cells in which the p53 response is
functionallycompromised,aroleofthisp53response
in modifying CtBP-dependent chemosensitivity has
not yet been established.
The aim of the present study, therefore, was to
establishthepatternsofexpressionandlocalizationof
CtBP1 and CtBP2, as well as their major isoforms, in
acommonhumanmalignancy,breastcancer.Wehave
examined how CtBP protein expression is regulated
in breast tumour-derived cells, and furthermore, how
CtBPs and p53 coordinately modulate the response
of these cells to cancer chemotherapeutic agents with
diverse mechanisms of action.
Results and discussion
CtBP proteins are expressed in breast cancer
We ﬁrst used Western blotting to determine the
expression of CtBP proteins in a panel of six widely
used breast cancer-derived cell lines (Figure 1A).
Using a monoclonal antibody (E12, Santa Cruz
Biotechnology) that was raised against human
CtBP1, which we have previously characterized
for its speciﬁcity towards CtBP1 and not CtBP2
(Bergman et al., 2009), a single band of approx.
47 kDa was detected in all of the lines, although one
line, SkBr3, was characterized by barely detectable
levels of CtBP1. Of the other lines there were more
modest (<2-fold) variations in CtBP1 abundance,
MCF-7 cells having slightly lower levels than the
remaining lines. A CtBP2-speciﬁc antibody that
was raised against amino acids 361−445 of murine
CtBP2 (BD-16/CtBP2, BD Biosciences), and binds
the extreme C-terminus of human CtBP2, recognizes
a clear double band in all the cell lines over the range
of 47−49 kDa. The abundance of these CtBP2 forms
varied by less than 2-fold across the panel of cell
lines. The intensity of the higher-molecular-mass
band was consistently the greater of the two.
We also compared representative breast cancer
lines with two non-transformed human cell lines:
hTERT-immortalized MRC-5 ﬁbroblasts and the
non-transformed breast epithelial cell line, MCF-
10A. Expression of CtBP1 and CtBP2 in MCF-7 and
MDA-MB-231 was comparable with that in MRC-5
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Figure 1 Expression of CtBP proteins in breast cancer
cell lines and breast tumour samples
CtBP1 and CtBP2 expression was determined by Western
blotting in (A) cell lines and (B) breast tumour samples. In (A),
relative quantiﬁcation of CtBP1 (solid bars) and CtBP2 (open
bars) is shown, normalized to actin (‘ND’ indicates not done,
due to multiple actin bands in this cell line). (C) Representat-
ive samples were probed with antibodies E12 or BD-3, both
raised against CtBP1. bc-2 and bc-9 are two of the breast
tumour samples from (B). CtBP1mh represents lysates from
HEK-293 cells transfected with a plasmid expressing CtBP1
with a 3 kDa C-terminal mychis tag; less protein was inten-
tionally loaded in this lane compared with the others.
cells, but approx. 3-fold higher than that in
MCF-10A.
We then performed comparable blots on samples
from a randomly selected series of ten fresh-
frozen breast cancer samples from the University of
Southampton Cancer Sciences Division tissue bank
(Figure 1B). The single CtBP1 band was present in
all the samples at approximately equal abundance,
none of these breast cancers appearing to lose CtBP1
expression.Interestingly,twoofthesamplesalsocon-
tained marked amounts of an apparent CtBP1 form
with a reduced electrophoretic mobility. This mo-
bility shift is equivalent to an increase of ∼3k D a ,
as it runs level on the gel with CtBP1-L with a
C-terminal tag of this size (Figure 1C). This band
in breast cancer sample number 9 was not, how-
ever, recognized by an antibody raised against the
C-terminus of murine CtBP1 (BD-3/CtBP1, amino
acids 345−441), even though the lower CtBP1 band
was detected by this antibody (Figure 1C). There-
forethishigher-molecular-massbandmaypotentially
represent either a protein that cross-reacts with E12
inthesesamples,apreviouslyundescribedspliceform
of CtBP1 that lacks the C-terminus, or CtBP1 with
a post-translational modiﬁcation that masks the epi-
tope for the C-terminal-directed antibody. No novel
bandsweredetectedinthebreastcancersampleswith
the anti-CtBP2 antibody, a doublet being observed
in all samples similarly to the cell lines.
We next examined the intra- and inter-cellular
distribution of CtBP proteins in the breast cancer
cells. Subcellular distribution in the MCF-7 line
was assessed using immunoﬂuorescence analysis of
paraformaldehyde-ﬁxedcellmonolayers.BothCtBP1
and CtBP2 were predominantly nuclear, although
some CtBP1 was also faintly detected in the cyto-
plasm, whereas CtBP2 was not (Figure 2A). We
then performed immunohistochemical analysis of
CtBP1 and CtBP2 expression in 22 breast tumour
samples, using formalin-ﬁxed, parafﬁn-embedded
archival samples from the Cellular Pathology De-
partment at Southampton General Hospital. The
primary antibody E12 was used to stain for CtBP1,
and separate sections were stained with two differ-
ent CtBP2 primary antibodies: BD-16 and E16 goat
polyclonal (Santa Cruz Biotechnology). Both CtBP2
antibodies produced similar staining patterns to each
other (results not shown), but the staining achieved
with the BD-16 antibody was generally more
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Figure 2 Inter- and intra-cellular distribution of CtBP proteins in breast cancer cell lines and breast tumour samples
(A) Cultured MCF-7 cells were analysed by immunoﬂuorescence for CtBP1 (E12 antibody) or CtBP2 (BD-16 antibody). Green
indicates CtBP proteins. Blue indicates DAPI (4 ,6-diamidino-2-phenylindole) staining for DNA. Scale bar, 10 μM. (B)R e p r e s e n t -
ative sections of benign breast tissue, and ductal carcinoma of the breast, stained for CtBP1 (E12 antibody) or CtBP2 (BD-16
antibody). The upper panel shows images from sections that contained no tumour tissue, the tissue having been removed from
a patient with a grade 2 ductal carcinoma. Scale bar, 100 μM.
intense and less patchy and therefore it was these
sections that were used for subsequent analysis. Both
proteins were expressed within the nuclei of benign
breastductsandlobules(Figure2B,upperpanel);ex-
pression was identiﬁed within epithelial and myoep-
ithelial cells but was sometimes less intense within
the latter (Figure 2B, upper panel). Both proteins
were also expressed within the nuclei of endothelial
cells and stromal cells. In addition, CtBP1 was ex-
pressed, usually less intensely, by lymphocytes. Both
CtBP1 and CtBP2 were widely expressed within the
nuclei of invasive and in situ carcinoma cells (Fig-
ure 2B, middle and lower panels, in situ carcinoma
not shown). CtBP1 and CtBP2 expression was de-
tected within the invasive tumour cells in all the
samples, with clear nuclear labelling in most of
thetumourcellsineachcase.WithneithertheCtBP1
nor CtBP2 antibody did we detect sufﬁcient vari-
ations in labelling intensity or distribution to enable
the development of a scoring system to distinguish
between the tumours. Staining in the tumour cells
was no more intense than that in benign breast tissue
(e.g. see Figure 2B, middle panel).
As far as it is possible to make comparisons there-
fore, the data from an immunohistochemical analysis
of breast tumour material are consistent with those
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fromWesternblottingofcelllines;breastcancercells
expressreadilydetectablelevelsofCtBP1andCtBP2,
which, with some exceptions (e.g. SKBr3 cells), do
notshowsubstantialvariationbetweentumours.The
abundance of CtBPs in tumour cells is comparable
with that seen in normal breast luminal epithelial
cells in vivo, as well as non-transformed ﬁbroblasts,
both in vivo and in vitro (i.e. MRC-5.hTERT.neo). In-
terestingly, we saw that expression in both normal
luminal breast epithelial cells and tumour cells is
higher than in the normal myoepithelial cells that,
along with the basal cells, surround the normal ducts
and lobules. Luminal and myoepithelial/basal cells
have very distinct gene-expression proﬁles and phen-
otypes, and whereas most of the breast tumours have
a luminal phenotype, cell lines such as MCF-10A
thatarederivedfromnormalbreastinvariablydisplay
characteristicsofthebasalcell(Wynford-Thomasand
Blaydes,1998;DiRenzoetal.,2002).Together,these
ﬁndings suggest that the increased abundance of Ct-
BPs in most of the breast cancer cell lines compared
with MCF-10A most likely reﬂects this phenotypic
difference, rather than any cancer-associated change.
It is noteworthy, however, that MDA-MB-231 cells,
which are representative of 10−15% of the breast
tumours that do have a basal-like phenotype, do have
elevated CtBP1 and CtBP2 levels compared with
MCF-10A.
CTBP1 and CTBP2 mRNAs encoding both long
and short forms of CtBP proteins are expressed in
breast cancer cells
The two forms of CTBP1 mRNA expressed in
human cells that encode CtBP1-L and CtBP1-
S/CtBP3/BARS proteins are distinguishable by the
inclusion of an additional exon (1α) in the CtBP1-
S encoding transcript (summarized in Bergman
et al., 2006), the result of which is that CtBP1-L
contains 11 more amino acids at the N-terminus
comparedwithCtBP1-S.Theconsequencesofthison
the function of the protein are unclear; CtBP1-S has
been extensively characterized as a cytoplasmic pro-
tein with roles in membrane ﬁssion and Golgi main-
tenance. CtBP1-L has been characterized primarily
as a transcriptional repressor, but while CtBP1-L has
been shown to function comparably to CtBP1-S in
the cytoplasm, whether CtBP1-S has transcriptional
repressor activity has not been determined. PCR ana-
lysis of mouse embryo ﬁbroblasts has shown both
splice variants to be present in these cells; however,
to our knowledge, no analysis of the relative expres-
sionlevelsofthesetwotranscriptsinhumancelllines
or tissues has yet been reported. We therefore per-
formed RT−PCR (reverse transcription−PCR) ana-
lysisofthebreastcancercelllinepanel,aswellasnon-
transformed MRC-5 and MCF-10A cells, amplifying
transcriptscontainingexons1−3ofCTBP1togener-
ate products from CTBP1-L and CTBP1-S (248 and
443 bp respectively, Figure 3A). In all the cell lines,
CTBP1-S was the predominant transcript present,
with CTBP1-L being detectable at low levels only.
With the exception of SKBr3 cells, in which CTBP1
transcripts were barely detectable, all the cell lines
appeared to express approximately equal amounts of
CTBP1-S mRNA. However, as the PCR reactions
were optimized for detection of all CTBP transcripts,
rather than relative quantiﬁcation between samples,
quantitative PCR for CTBP mRNA was performed
(Figure3A,histogram).Thisrevealedagreaterdegree
of variation, although again the CTBP1 transcripts
were barely detectable in SKBr3. CTBP1 mRNA
abundance in MCF-10A was not lower than that in
thecancercelllines,indicatingthatthereducedCtBP
protein abundance in these cells is due to differential
regulation at the post-transcriptional level. We also
examined the breast cancer samples for CTBP1 tran-
script expression; again both transcripts were present
inmostofthesamples,andwhileCTBP1-Swasagain
thepredominanttranscriptinsomesamples,thiswas
not the case in all the tumour samples (Figure 3B).
This may reﬂect variation between breast cancer cells
derived from different patients, or possibly differ-
ential content of stromal and inﬂammatory cells in
the tumours. Together, these results indicate that
the single protein band observed in Western blots
contains both CtBP1-L and CtBP1-S, with CtBP1-S
presumably being the predominant form in the cell
lines.
CtBP2 protein shows a clear doublet on Western
blots that, on the basis of conclusions made by Ver-
ger et al. (2006), are likely to consist of CtBP2-L and
CtBP2-S that differ in size by 25 amino acids. The
additional amino acids in CtBP2-L contain a basic
KVKRQR motif, which may well contribute to the
altered mobility of the two proteins in SDS/PAGE,
but more importantly this region functions as a
nuclear localization or retention sequence (Bergman
et al., 2006; Verger et al., 2006; Zhao et al., 2006)
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Figure 3 Expression of CTBP mRNA transcripts in breast
cancer cell lines and breast tumour samples
cDNA was derived from mRNA extracted from cell lines (A)
or breast tumour samples (B) and ampliﬁed by PCR using
primersspeciﬁcforthe5  regionsofCTBP1andCTBP2mRNA
to determine the expression of the mRNAs encoding the
L- and S-forms of each CtBP protein. The histogram in (A)
shows results from a TaqMan quantitative PCR analysis of
CtBP1 (solid bars) and CtBP2 (open bars) in the cell lines.
and as such potentially has a clear inﬂuence on the
function of CtBP2-L as a transcription factor. Verger
et al. (2006) used RT−PCR of murine foetal liver to
demonstrate the presence of transcripts lacking the
ﬁrst coding exon of ctbp2-L that would be predicted
toinitiatetranscriptionatanalternativeATGpresent
inthenextcodingexon(exon4)togenerateCtBP2-S.
As far as we are aware, however, this analysis has not
been performed in human cells, and the derivation
of the two human isoforms of CtBP2 has not been
determined. We therefore performed PCR-analysis
of the 5 -region of CTBP2 in the breast cancer cell
lines, to amplify transcripts containing exons 2−6.
CTBP2-L mRNA is predicted to generate a band of
571 bp in this assay, and this was indeed the pre-
dominant band obtained in all the breast cancer cell
lines and tumour samples. However, a smaller band
was also obtained in all the cell lines and in most
of the breast cancer samples (Figures 3A and 3B).
Both bands were isolated from RT−PCRs of MCF-7
cDNA,clonedandsequenced.Thelargerbandcorres-
pondedtothepredictedCTBP2-Lsequences,andthe
smaller band was 471 bp and lacked exon 3, which is
the ﬁrst coding exon in the human CTBP-L coding
sequence. Therefore, as is the case in the mouse, this
transcriptwouldbetranslatedintoCtBP2-Sfromthe
ATG in exon 4.
However, we did note that the CTBP2-S mRNA
was generally only expressed at very low levels com-
pared with CTBP2-L, whereas the difference in the
abundance of the two encoded protein isoforms was
rather less marked (Figure 1). We therefore asked
whether the CTBP2-L mRNA has the potential to
be translated into both proteins, as it contains both
ATGsatcodons1(exon3)and26(exon4).Weprevi-
ouslyisolatedaCTBP2clonefromaHeLacDNAlib-
rary that contains 233 bp of 5 -UTR (5 -untranslated
region) sequence, in addition to the complete coding
sequence of CTBP2-L, and thus can be used to assess
sites of translational initiation from the CTBP2-L
splice form of the mRNA. This cDNA was cloned
into the pCDNA3.1 expression vector and transfec-
ted into HEK-293 cells (human embryonic kidney
cells). Endogenous CtBP2 in this cell line is present
in the doublet form (Figure 4A), and transfection
of increasing amounts of pcDNA3.1CtBP2 vector
resulted in the abundance of both forms increasing,
suggesting that both proteins are translated from a
single cDNA (Figure 4B). To conﬁrm this, vectors in
whichthetwoATGswereindividuallymutatedwere
transfected:lossofATG1(codon1)clearlyresultedin
thesynthesisofCtBP2-Sonly,whereasonlyCtBP2-L
wassynthesizedwhenATG2(codon26)wasmutated
(Figure 4C). Thus, in human cells, CtBP2-S may be
synthesized as a result of both alternative splicing
and the use of alternate translation start sites in the
CTBP2-L mRNA.
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Figure 4 Role of an alternate translation initiation start
site in the synthesis of CtBP2-S
(A) mRNAs from the indicated cell lines were analysed by
RT−PCR for CTBP2 splice form expression, as in Figure 3.
(B) HEK-293 cells growing in 60 mm dishes were transfected
with the indicated amount of vector containing CTBP2 cDNA,
or empty vector, and lysates were prepared for Western-blot
analysis 48 h later. (C) HEK-293 cells were transfected with
4 μg of the indicated CtBP2 expression vector and CtBP2
protein isoform expression was determined.
An autoregulatory feedback loop maintains CtBP
protein abundance in proliferating breast cancer
cells, and is disrupted in response to stress
signalling
Using siRNA reagents to block the expression of
both CtBP1 and CtBP2 together, we have previ-
ously demonstrated that CtBPs play an important
role in the proliferation and survival of breast can-
cer cells (Bergman et al., 2009). However, because
CtBP1 and CtBP2 potentially have some important
functional differences, we wished to examine the ef-
fects of blocking the expression of each gene product
independently. Figure 5(A) (Western blot and quan-
tiﬁcation) demonstrates the efﬁcacy of the siRNAs
to CTBP1 and CTBP2 in blocking the synthesis
of the two proteins in MCF-7, MDA-MB-231 and
MRC5.hTERT.neo cells, either individually (CtBP1
or CtBP2) or in combination (CtBP1+CtBP2).
CtBP1/2 is a single siRNA that targets the mRNAs
derived from both CtBP-encoding genes. In doing
theseexperiments,inadditiontotheexpectedknock-
down of the target of the siRNA, we made the con-
sistent observation that inhibition of CtBP1 syn-
thesis alone results in an increase in the abundance
of CtBP2 protein. This occurred in the two breast
cancer cell lines we studied, as well as in the non-
transformed ﬁbroblast line, MRC5.hTERTneo. In
contrast,CTBP2siRNAdidnotaffectCtBP1protein
abundance. This indicates that cells posses a mech-
anism for maintaining homoeostasis of CtBP pro-
teinabundancethroughthecontrolofCtBP2protein
levels. This appears to be a post-transcriptional effect
on CtBP2, as CtBP1 siRNA does not up-regulate
the abundance of CTBP2 mRNA, as determined by
quantitative RT−PCR (Figure 5B).
We have investigated this regulation of CtBP
abundance further in the experiment described in
Figure 5(C). MDA-MB-231 cells were transfected
with an expression vector for a C-terminally tagged
CtBP2 protein (CtBP2-TT), and stably expressing
clonesestablished.TheCtBP2-TTvectorhasalsohad
introduced synonymous mutations in the target re-
gionoftheCtBP1/2siRNA.AsshowninFigure5(C),
CtBP2-TT protein was expressed at approximately
identical abundance to endogenous CtBP2 in the se-
lected clone (similar levels were observed in other
clones). When endogenous CtBP protein expression
was inhibited with CtBP1/2 siRNA, the expected
decrease in endogenous CtBP2 was observed; how-
ever, there was a marked increase in the abundance of
CtBP2-TT. This effect is consistent with our obser-
vations of endogenous CtBP2 when CtBP1 siRNA
was used. It also conﬁrms that this feedback reg-
ulation of CtBP2 protein abundance occurs at the
post-transcriptional level, as CtBP2-TT expression is
driven by the CMV (cytomegalovirus) promoter in
the expression vector, which is unlikely to be un-
der the same control as the endogenous CTBP2 pro-
moter.Todeterminewhetherthisregulationinvolves
proteasome-dependent degradation, the cells were
transfected with control or CtBP1/2 siRNA and, at
27 h post-induction, cells were treated with the pro-
teasome inhibitor MG132 (carbobenzoxy-L-leucyl-
L-leucyl-leucinal; Figure 5D). In control siRNA-
treatedcells,thisresultedinanincreaseinCtBP2-TT
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Figure 5 Evidence that CtBP2 protein abundance in cells is regulated by an auto-regulatory feedback loop
Legend on next page.
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(A) Cells were transfected with siRNA reagents that either target both CTBP1 and CTBP2 together (CtBP1/2), independently
(CtBP1 or CtBP2) or a combination of the two independently targeting siRNAs (CtBP1+CtBP2). Lysates were prepared for
Western blotting 48 h after transfection. Quantiﬁcation of Western blotting results is shown and is representative of 11 separate
experiments in MCF-7 cells, in which eight showed a CtBP1 siRNA-induced increase in CtBP2 of up to 70%. (B) MCF-7 cells
were transfected with the indicated siRNA. Lysates prepared 72 h after transfection were analysed for expression of the CTBP
mRNAs using quantitative RT−PCR. (C) MDA-MB-231 cells stably expressing tagged, CtBP1/2 siRNA-insensitive CtBP2 were
transfected with CtBP1/2 siRNA and lysates were prepared for Western blotting at the indicated times post-transfection. E16
antibody was used to detect CtBP2, as the C-terminal tag obscures the epitope for BD clone 16 antibody. (D) MDA-MB-231
cells stably expressing tagged, CtBP1/2 siRNA-insensitive CtBP2 were transfected with either control or CtBP1/2 siRNA. At
27 h post-transfection, cells were treated with 50 μM MG-132 for the indicated times. E16 antibody was used to detect both
the tagged and endogenous CtBP2.
protein abundance of over 3-fold within 3 h, in-
dicating that the protein is subject to proteasome-
dependent degradation. Endogenous CtBP2 and
CtBP1 protein abundance also increased. In CtBP1/2
siRNA-treated cells, endogenous CtBP1 and CtBP2
did not increase in response to MG-132, as their syn-
thesis was blocked by the siRNA. CtBP2-TT abund-
ance was elevated compared with control siRNA-
transfected cells (see the inset to Figure 5D), but was
not further increased by MG-132. This demonstrates
thatinhibitingthesynthesisoftheendogenousCtBP
proteinsresultsinalossofproteasome-dependentde-
gradation of the exogenous CtBP2-TT.
The post-transcriptional regulation of CtBP pro-
tein abundance is known to be important in both
tumour initiation (Phelps et al., 2009) and the re-
sponse to genotoxic stress and cancer chemothera-
peutics (Zhang et al., 2003; 2005; Paliwal et al.,
2006; Wang et al., 2006). In the main, these studies
have focused on CtBP1; CtBP2 is also known to be
degraded in response to UV radiation damage (Pali-
wal et al., 2006) although the reported effects of this
stress on CtBP2 abundance appear to be less than
those reported for CtBP1 (Zhang et al., 2003), albeit
the experimental systems used in the separate studies
notbeingdirectlycomparable.Toourknowledge,the
relative effect of genotoxic stress on the abundance of
CtBP1 compared with CtBP2 has not been directly
investigated in the literature. We therefore wished
to determine whether the autoregulatory mechan-
ism controlling CtBP2 abundance might function in
response to stress-induced CtBP1 degradation, and
result in a differential effect of stress on the expres-
sion of these two proteins. Figure 6(A) shows that,
in normally proliferating MCF-7 cells, blockade of
protein synthesis by cycloheximide for 16 h does not
decrease the abundance of CtBP1 or CtBP2. This is
consistent with the abundance of CtBP proteins be-
ing tightly regulated at the post-transcriptional level
such that their levels do not decrease rapidly when
their synthesis is blocked. Therefore any effects of
genotoxic stress on the abundance of CtBPs within
this time scale should involve increased rates of pro-
tein degradation, rather than inhibition of protein
synthesis. MCF-7 and MDA-MB-231 cells were then
exposed to increasing doses of UV-C radiation and
examined by Western blotting 16 h later. In MCF-7
cells, 5 J/m2 UV-C induced the stabilization of p53
protein,conﬁrmingtheactivationofstress-responsive
signalling pathways at this dose (Figure 6B). Higher
doses appeared to attenuate this response, presum-
ably due to non-speciﬁc cell damage. Both CtBP1
and CtBP2 protein abundance was markedly reduced
in MCF-7cells inresponse to 5J/m2 U V - C ,a sw e l la s
higherdoses(Figure6B).InMDA-MB-231thesame
doses of UV-C had a negligible effect on the abund-
ance of CtBP1 or CtBP2 (Figure 6C; p53 protein
abundance was also not affected, this being due to
the presence of a stable mutant p53 protein in these
cells). Comparable experiments were then performed
using cisplatin, the cells being continuously exposed
to the drug for 16 h. In MCF-7 cells, p53 stabiliza-
tion was observed at 25 μM cisplatin; a decrease in
CtBP2 abundance also occurred at this concentration
(Figure 6D), and 50 μM cisplatin caused a marked
reduction in both CtBP1 and CtBP2. As was the case
forUV-C,cisplatinessentiallyfailedtopromoteCtBP
degradation in MDA-MB-231 cells (Figure 6E). Fi-
nally, we wished to determine whether a broader
range of chemotherapeutic drugs affected CtBP
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Figure 6 Regulation of the abundance of CtBPs by genotoxic and chemotherapeutic agents in breast cancer cells
(A) MCF-7 cells were exposed to 100 μg/ml cycloheximide to inhibit protein synthesis for the indicated time periods be-
fore cell lysis for Western-blot analysis. (B) MCF-7 cells were irradiated with the indicated dose of UV-C and harvested 16 h
later for Western blotting. (C) MDA-MB-231 cells were irradiated with the indicated dose of UV-C and harvested 16 h later.
(D) MCF-7 cells were exposed to the indicated concentrations of cisplatin for 16 h. (E) MDA-MB-231 cells were exposed to the
indicated concentrations of cisplatin for 16 h. (F) MCF-7 cells were incubated for 24 h with the following compounds at their IC50
concentration: 5-ﬂuorouracil (12.5 μM), Taxol (4.13 nM), etoposide (1.56 μM) and cisplatin (15.5 μM) before analysis of CtBP
abundance by Western blotting.
proteinabundance.Cellproliferationassayswereused
to determine the IC50 values for the drugs in MCF-7
cells (results not shown and Figure 8), which were
then exposed for 24 h to IC50 concentrations before
Western blotting (Figure 6F). Cisplatin (15.5 μM)
caused a reduction in CtBP2 (note that while the
concentration is lower than the minimum required
for observing an effect in Figure 6D, the treatment
time of 24 h is longer). At IC50 concentrations, none
among 5-ﬂuorouracil, Taxol and etoposide promoted
the degradation of either CtBP1 or CtBP2, indicat-
ing that induced CtBP protein degradation is not a
general response to all forms of genotoxic stress.
Together, these data demonstrate that both UV
radiation and cisplatin, which have previously been
shown to promote the degradation of CtBP proteins
in other experimental models, also do so in the MCF-
7 breast cancer cell line. At least in the case of cis-
platin,theseeffectsdooccuratconcentrationswithin
the range of the IC50 and so could potentially con-
tribute to the antiproliferative activity of the drug.
UV-C affected the abundance of both CtBP1 and
CtBP2 proteins to a comparable extent, whereas cis-
platin appeared to down-regulate CtBP2 at slightly
lower concentration than was required for its effect
on CtBP1. This suggests that the feedback mech-
anism whereby CtBP2 protein abundance is main-
tainedorincreasedinresponsetodecreasedCtBPpro-
tein synthesis does not function in response to stress
signalling-induced degradation of CtBPs. Neither
UV-C nor cisplatin had any substantial effect on the
abundance of CtBP proteins in the MDA-MB-231
cell line, even at doses severalfold higher than were
effective in MCF-7. There are many phenotypic and
genetic differences between these two cell lines, and
hence it is not possible to directly infer any mech-
anistic details from this difference; however, we have
performed a characterization of some of the known
key regulators of CtBP protein abundance in the cell
lines (Figure 7). HIPK2 is expressed in both MCF-7
and MDA-MB-231 cells (Figure 7A), and hence the
lack of UV-C-induced CtBP protein degradation in
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Figure 7 Status of known regulators of CtBP degradation in breast cell lines
(A) The abundance of HIPK2 and p14ARF-encoding mRNAs was determined by RT−PCR (left panel) and HIPK2 protein by
Western blotting (right panel). (B) APC protein was detected by immunoﬂuorescence microscopy: green, APC; blue, DAPI
staining of DNA. APC mRNA transcripts derived from promoter A or B were determined by RT−PCR.
MDA-MB-231 cells cannot be attributable to loss
of this signalling kinase. Like HIPK2, p14ARF can
also be required for UV-radiation-induced CtBP2
degradation (Paliwal et al., 2006); however, MCF-
7 cells express neither p14ARF-encoding mRNA nor
p14ARF protein(Stottetal.,1998;Saadatmandietal.,
2002) (see Figure 7A for conﬁrmation of these previ-
ous reports). Thus stress-inducible down-regulation
ofCtBPabundancedoesnotappeartorequirep14ARF
in the MCF-7 breast cancer cell line. APC is known
to promote the proteasome-mediated degradation of
CtBP1 (Nadauld et al., 2006) and APC mutation
correlates with an increase in CtBP1 abundance in
early-stage colorectal tumours (Phelps et al., 2009),
although a role of APC in stress-inducible degrada-
tion has not been described. Both MCF-7 and MDA-
MB-231 cells are known to express functional APC
protein (Smith et al., 1993); however, we did ﬁnd the
abundance of APC protein in MDA-MB-231 cells to
be markedly lower than that in MCF-7 (Figure 7B).
Interestingly,theabundanceofAPCinbothlineswas
very much lower than that in MCF-10A. The expres-
sion of APC may be down-regulated in cancer cells
due to promoter methylation (Tsuchiya et al., 2000);
however, RT−PCR analysis indicated that this was
not the cause for the differential APC protein abund-
ance in these three lines (Figure 7B). These results
suggest that the low levels of CtBP proteins in MCF-
10A cells could potentially be due to high levels
of APC-dependent degradation. It is also possible
that the differential response of CtBPs to genotoxic
stress between MCF-7 and MDA-MB-231 may re-
late to differences in their APC levels; in both cases
further work will be required to clarify the inter-
play between APC and CtBPs in breast epithelial
cells.
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Inhibition of CtBP expression sensitizes breast
cancer cells to diverse chemotherapeutic agents
Previous studies have demonstrated that loss or re-
duction in CtBP family proteins can sensitize some
cell lines to cell killing by certain chemotherapeutic
agents, speciﬁcally etoposide and cisplatin having
beenexamined(Grooteclaesetal.,2003;Wangetal.,
2006). We wished to extend these studies to breast
cancer-derived cells treated with a wider range of
chemotherapeutics with distinct mechanisms of ac-
tion. Given recent data on the functional differences
between CtBP1 and CtBP2, as well our present res-
ults demonstrating feedback regulation of CtBP2,
we also wished to compare the effects of reagents
targeting either CtBP1 or CtBP2 individually in
these assays. Finally, the pro-apoptotic effects have
been demonstrated to occur independently of p53;
however, we have recently demonstrated that loss of
CtBP1 and CtBP2 does lead to p53 activation, and
this can protect against CtBP siRNA-induced apop-
tosis, and hence we examined the role of p53 in CtBP
siRNA-induced chemosensitization in breast cancer
cells.
MCF-7 cells were transfected with combinations
of control, CtBP1, CtBP2, CtBP1/2 and p53-speciﬁc
siRNAs such that the total amount of siRNAs
transfected was identical in each case. Western
blotting of cell lysates 72 h post-transfection
conﬁrmed that CtBP- and p53-targetting siRNAs
retain their efﬁcacy when applied in combination
and with a chemotherapeutic agent (Figure 8A). As
we have shown previously, p53 protein abundance
increased in response to the combined knockdown
of CtBP1 and CtBP2, using either the CtBP1/
2 siRNA or a combination of CtBP1 and CtBP2
siRNAs. Knockdown of either CtBP1 or CtBP2 in
isolation did not affect p53 abundance (results not
shown). The effects of the siRNA combinations on
overall cell proliferation in the absence of additional
chemotherapeutics were then determined by a
96-well plate MTS [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] proliferation assay. At 7 days after cell
transfection, equal numbers of cells are plated on
the wells 2 days post transfection (Figure 8B). The
MTS assay measures cellular reducing potential to
determine changes in the numbers of metabolically
active cells and thus integrates the combined effects
of inhibition of cell division and induction of cell
death over the treatment period. CtBP1 depletion
alone caused a small reduction in MCF-7 cell
proliferation to 92.6% of control siRNA-treated
cells. CtBP2 siRNA had a greater effect, prolifer-
ation being reduced to 76.4%. Given the Western
blotting results, this differential response to CtBP1
and CtBP2 siRNAs is unlikely to be due to any
differential efﬁcacy of the siRNAs on their respective
targets and suggests that CtBP2 is more critical than
CtBP1 in the maintenance of proliferative capacity
in these cells. This ﬁnding is consistent with the
results from knockout mouse studies (Hildebrand
and Soriano, 2002), as well as a previous study
looking at apoptosis in colon cancer cell lines
induced by CtBP1 versus CtBP2 siRNA (Paliwal et
al., 2006). Inhibition of expression of both CtBPs
reduced proliferation to 68.0% or 66.0% depending
on whether the single CtBP1/2 siRNA or the CtBP1
and CtBP2 siRNA combination was used. Inhibition
of p53 expression on its own caused a small reduction
in proliferation, and also reduced proliferation in the
presence of CtBP1/2 siRNAs, to 60% of untreated
cells. These conﬁrm our previous ﬁndings that loss of
both CtBPs has anti-proliferative effects in MCF-7
cells, which are not dependent upon p53, and that
lossofp53furthersensitizesthecellstolossofCtBPs.
We showed previously that the antiproliferative
effects of CtBP 1 and 2 knockdown in these cells is
primarily through cell cycle arrest, with a switch to
an apoptotic response occurring when p53 is lost.
BecausetheMTSassayusedheredoesnotdistinguish
between these two mechanisms of reduction in the
numbersofviablecells,wealsoperformedtime-lapse
video-microscopy of cells, which again conﬁrmed
this (see Supplementary Movies 1−4 at http://www.
biolcell.org/boc/103/boc1030001add.htm). Cells
were treated as per the Western blot in Figure 8(A),
and after 72 h, the medium was replaced and
video-microscopy commenced. Combined knock-
down of CtBP1 and CtBP2 resulted primarily in
cytostasis, with an increase in the proportion of the
remaining mitoses that are aberrant (Supplementary
Movie 2). p53 siRNA on its own had little effect
(Supplementary Movie 3), but when combined with
knockdown of both CtBP proteins, reduced the
cytostatic effect of CtBP loss, and increased cell
death (Supplementary Movie 4).
To assess the chemo-sensitizing effects of the
siRNA combinations, cells were transfected with
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Figure 8 Depletion of CtBPs enhances the sensitivity of MCF-7 cells to cancer chemotherapeutics
(A) Cells were transfected with the indicated siRNAs (50 nM total siRNA concentration). After 48 h, 5-ﬂuorouracil was added
where indicated, and lysates were prepared for Western blotting a further 24 h later. (B) The effects of the indicated siRNAs on
cell survival were determined by MTS assay 7 days after transfection (n=16 for each data point). (C−F) Effect of the indicated
siRNAs on the IC50 of the cells for 5-ﬂuorouracil (C), Taxol (D), etoposide (E) and cisplatin (D). Results in each graph represent
the means for three independent experiments.
siRNA,andtransferredto96-wellplates2 dayslater;
then 1 day later the drug was applied and cells were
left for 1 day, after which the cells were cultured in a
fresh medium for a further 3 days. Independent IC50
values for the drugs for each siRNA combination
were then calculated for these experimental condi-
tions. The anti-metabolite 5-ﬂuorouracil (Figure 8C)
had an IC50 of 118 μM in control siRNA-transfected
cells. Despite having a relatively modest effect on
untreated cells, CtBP1 siRNA signiﬁcantly reduced
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the IC50 for 5-ﬂuorouracil to 66.7 μM, the effect
of CtBP2 siRNA on IC50 being somewhat greater
than this (decreased to 43.3 μM). The IC50 was fur-
ther reduced to 29.5 or 27.6 μMw h e nb o t hC t B P 1
and CtBP2 expression was inhibited by the CtBP1/2
or CtBP1&2 siRNAs respectively. When transfec-
ted on its own, siRNA to p53 increased the IC50
slightly, although not signiﬁcantly. In contrast to
this effect under conditions when CtBPs were ex-
pressed normally, when CtBP1 and CtBP2 expres-
sion was inhibited, loss of p53 further sensitized the
cells to 5-ﬂuorouracil (IC50 =16.4 μM). To exam-
ine these effects in more detail, we again performed
time-lapsevideo-microscopy,cellsbeingtreatedwith
5-ﬂuorouracil for 24 h before commencement of the
imaging period. In the absence of CtBP knockdown,
5-ﬂuorouracil was primarily cytostatic (see Supple-
mentary Movie 5 at http://www.biolcell.org/boc/
103/boc1030001add.htm), this cytostatic effect be-
ing somewhat reduced by p53 knockdown (see
Supplementary Movie 7 at http://www.biolcell.org/
boc/103/boc1030001add.htm). In CtBP-depleted
cultures, 5-ﬂuorouracil increased cell death (Sup-
plementary Movie 6 at http://www.biolcell.org/
boc/103/boc1030001add.htm); clearly, this effect
was most pronounced in the absence of p53
(compare Supplementary Movie 4 with Supple-
mentary Movie 8 at http://www.biolcell.org/boc/
103/boc1030001add.htm).
The microtubule-stabilizing agent Taxol (Fig-
ure 8D) has an entirely different mechanism of action
to 5-ﬂuorouracil, and hence it was of interest to es-
tablish whether the effects of CtBP siRNA were sim-
ilar.Incontrastto5-ﬂuorouracil,p53siRNAslightly
sensitized cells to Taxol, reducing the IC50 from 5.45
to 2.99 nM. Again this effect was not signiﬁcant, al-
though such an effect would be consistent with pub-
lished results demonstrating that wild-type p53 is
protective for microtubule-targeting drugs in cancer
cells (Stewart et al., 1999). Inhibiting the expres-
sion of the CtBP proteins demonstrated a similar
pattern of effects on the IC50 as was seen in
5-ﬂuorouracil-treated cells, individual siRNA to
CtBP2 alone having a greater effect than CtBP1
siRNA, although in this case experimental variabil-
itywashigherthanthatobtainedwith5-ﬂuorouracil,
andneithereffectoftheindividualsiRNAswassigni-
ﬁcant. Combined CtBP knockdown had greater and
signiﬁcant effect, and loss of p53 reduced the IC50
further still. An essentially similar pattern was seen
with the genotoxic agents cisplatin and etoposide
(Figures8Eand8Frespectively),ineachcasetheIC50
in the presence of combined inhibition of CtBP1 and
CtBP2 expression being 2.7−2.8-fold lower than in
controltreatedcells,andlowerstillwhenp53expres-
sion was blocked.
Overall, while we have shown that a substantial
reduction in the abundance of CtBPs is not a gen-
eral occurrence in response to all forms of genotoxic
stress, the chemo-sensitizing effects of suppressing
CtBP protein expression do occur in response to
treatment with chemotherapeutic agents that have
diverse mechanisms of action. This suggests that,
rather than speciﬁcally modulating the pathways in-
duced in response to the chemotherapy, the role of
CtBPsinchemo-resistance may bethroughpathways
with broad effects on cell proliferation and survival,
such as suppression of pro-apoptotic gene expres-
sion (Grooteclaes et al., 2003; Kovi et al., 2010),
and the maintenance of mitotic ﬁdelity (Bergman
et al., 2009). Additionally, CtBP1 has been shown
to promote drug resistance by increasing expression
of the MDR1 (multi-drug resistance 1) gene (Jin
et al., 2007); this provides an additional mechan-
ism whereby siRNAs to CtBPs may increase chemo-
sensitivity. It is potentially interesting, however, that
the greatest effect was observed in response to 5-
ﬂuorouracil.Thiswasparticularlyapparentincellsin
which p53 expression was inhibited, in which com-
bined CtBP1 and CtBP2 knockdown reduced the
IC50 for 5-ﬂuorouracil by 7.8-fold. The mechanistic
basis of this is currently unclear, although it is of
interest that, compared with other genotoxic agents,
the antiproliferative affects of 5-ﬂuorouracil can be
shown to be highly dependent on the presence of a
functional p53 response pathway (Bunz et al., 1999).
It is clear from our data that, particularly in cells that
cannotundergop53-dependentapoptosisorcellcycle
arrest, CtBPs play an important role in protecting
cells from the pro-apoptotic effects of 5-ﬂuorouracil.
Notwithstandingtherequirementforfurtherwork
to fully understand the mechanistic basis of CtBP-
regulated chemosensitivity, this effect of CtBP
siRNA on the cellular response to 5-ﬂuorouracil in
particular clearly represents a substantial sensitizing
effect of a chemotherapeutic agent that is widely
used in the therapy of cancer, including the ther-
apy of breast cancer. Thus factors that affect CtBP
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protein activity in cells, particularly those in which
p53 function is lost by p53 gene mutation, could
potentially inﬂuence the response of tumours to this
treatment. Such factors that exist within a tumour
environment include hypoxia and enhanced aerobic
glycolysis, which both increase intracellular NADH
and thus promote the formation of CtBP dimers and
CtBP chromatin-modifying complexes (Zhang et al.,
2002, 2007). That these complexes can be recrui-
ted to chromatin to suppress the expression of
pro-apoptotic BH3-only genes (Kovi et al., 2010)
suggests that hypoxia-induced CtBP protein dimer-
ization would be chemo-protective under these con-
ditions. It is important to note, however, that our
siRNA experiments will clearly deplete cells of both
monomeric and dimeric CtBP proteins and so do not
formally exclude a role for monomeric CtBPs in the
chemo-resistance mechanism.
The present study has also identiﬁed some import-
antnovelaspectsoftheregulationofCtBPproteinex-
pressionthatwillberelevanttofuturestudiesofthese
molecules. First, our RNA analysis has demonstrated
that the predominant form of CtBP1 expressed in a
panel of commonly studied breast cancer cell lines is
CtBP1-S, rather that the CtBP1-L form that was ori-
ginallyclonedfromHeLacells(Schaeperetal.,1995)
anduponwhichallthemechanisticstudiesoftherole
of CtBP1 proteins as transcriptional repressors have
been performed. Indeed, to date, functional studies
on CtBP1-S have exclusively focused on its role in
the cytoplasm as a regulator of vesicular membranes
(Corda et al., 2006). CtBP1-L and CtBP1-S proteins
only differ by 11 amino acids at their N-terminus,
and are indistinguishable by standard Western-blot
analysis. This region of the molecule is not known to
have any functional role; however, this clearly war-
rants further analysis. As far as we are aware the only
comparableanalysisofCtBP1isoformexpressionthat
has been published examined murine embryo ﬁbro-
blasts, and also found the CtBP1-S encoding splice
form to be somewhat more abundant than that en-
coding CtBP-L (Yang et al., 2006) in these cells.
We have also shown that the overall abundance of
CtBP proteins in cells is controlled through what ap-
pearstobeanauto-regulatoryfeedbackloopthatreg-
ulatesCtBPproteinsatthepost-transcriptionallevel.
The mechanism for this remains to be determined,
although we have shown that it involves the regu-
lation of the rate at which the protein is degraded.
The APC protein has been demonstrated to control
CtBP proteinturnover inother experimental systems
and, given that it is expressed in a functional form
in the cell lines we have examined, may potentially
be involved in this auto-regulation of CtBP abund-
ance. APC is known to regulate the abundance of
CtBP1, whereas we only found an increase in CtBP2
abundanceinresponsetoCtBP1siRNA,andnotvice
versa. This result suggests a CtBP2-selective regulat-
orymechanism,althoughasimplerexplanationcould
be that CtBP1 may be more abundant in cells than
CtBP2, so that knockdown of CtBP2 results in an
undetectable relative increase in CtBP1 abundance
to restore total CtBP protein levels. Whatever the
mechanism, the presence of a pathway that main-
tains the homoeostasis of CtBP protein abundance
in proliferating cells is perhaps not surprising, given
thecriticalroleoftheseproteinsinsomanypathways
that deﬁne the cellular phenotype.
Materials and methods
Cell culture and reagents
Primary human breast cancer material was obtained from the
Southampton Cancer Research UK tumour bank; the cohort
of formalin-ﬁxed, parafﬁn-embedded archival breast cancer tis-
sue from 144 consecutive patients with available tissue block
has been previously described (Cutress et al., 2003). A total of
22 consecutive blocks from this cohort were analysed: of these,
18 were from patients with ductal carcinoma; the remainder
were lobular carcinoma. All human tissue was assayed with
local ethics committee approval. Culture of the panel of hu-
man breast cancer lines has been described previously (Phelps
et al., 2003). Medium for MCF-10A was supplemented with
500 ng/ml cortisol and 0.01 mg/ml insulin. MRC-5.hTERTneo
are an immortalized derivative of MRC-5 ﬁbroblasts (McSharry
et al., 2001), and were cultured in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen) supplemented with 10% (v/v) foetal calf
serum. Transfection of plasmids into cells, as well as siRNA into
MRC-5.hTERT.neocells,wasperformedusingLipofectamineTM
2000 reagent (Invitrogen). Breast cancer cell lines were trans-
fected with siRNA at a combined concentration of 50 nM using
INTERFERinreagent(PolyplusTransfection).siRNAsreagents
targetingCTBP1/2,CTBP1,CTBP2andTP53mRNAs,aswell
as control siRNAs, have been described previously (Bergman
et al., 2009). CtBP1mh plasmid was generated by cloning the
human CTBP1 coding region into pcDNA3.1mychisA vector.
To generate pcDNA3.1CtBP2, the human CTBP2 cDNA was
excised from pBSK-CtBP2 (Mirnezami et al., 2003) and ligated
into pcDNA3.1. Derivative plasmids containing mutations of
the ATGs at codon 1 and codon 26 were generated by site-
directed mutagenesis. pcDNA3.1-CTBP2-TT expresses CtBP2
with a C-terminal tandem afﬁnity puriﬁcation tag; the plas-
mid also contains a synonymous mutation of the target region
of the CtBP1/2 siRNA, which was introduced by site-directed
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mutagenesis. Cells were exposed to UV-C radiation using an
XL-1000 UV cross-linker (Spectronics).
Cell proliferation assay and statistical analysis
For cell proliferation assays, cells were plated at 2000 cells per
well on 96-well plates; when combined with siRNA knock-
down analysis, plating was 48 h after siRNA transfection. At
24 h after plating, the medium was replaced with 100 μlo fa
mediumcontainingserialdilutionsofachemotherapeuticagent,
the ﬁnal concentration of the solvent DMSO was 0.5% in all
wells. All conditions were assayed in duplicate. After 24 h the
drugs were removed and a fresh medium was added; cells were
cultured for a further 96 h before performing an MTS-based cell
proliferation assay (CellTitre Aqueous One Cell Proliferation as-
say; Promega). IC50 values were generated from the results by
using Prism software (GraphPad Software). Results of the drug
response experiments are expressed as means+ −S.E.M. of IC50.
Statisticalsigniﬁcancewasevaluatedusingtheone-wayANOVA
parametric test and Tukey’s post hoc test. *P< 0.05, **P<
0.01. Time-lapse video-microscopy was performed as described
previously (Bergman et al., 2009).
Protein analysis
Cells lines in culture were washed with PBS, pelleted by
centrifugation at 1000 g for 5 min, snap-frozen and stored at
−80◦C. Sample lysis and immunoblotting were performed as
described previously (Blaydes and Hupp, 1998). Membranes
were probed for CtBP1 using either mouse monoclonal E12
[Santa Cruz Biotechnology; this was raised against amino
acids of human CtBP1 and does not recognize human CtBP2
(Bergman et al., 2009), see also Figure 5A] or, where speciﬁc-
ally stated, mouse monoclonal BD-3/CtBP1 (BD Biosciences;
raised against amino acids 345−441 of mouse CtBP1). CtBP2
was detected using mouse monoclonal BD-16/CtBP2 (BD Bios-
ciences), raised against either amino acids 361−445 of mouse
CtBP2 or, where speciﬁcally stated, goat polyclonal E16 (Santa
Cruz Biotechnology; raised against a peptide from near the
C-terminus of human CtBP2). Other antibodies were used
to detect p53 [DO-1 (Serotec)]; HIPK2 [ab57328 (Abcam)]
and β-actin (Sigma). Images were captured and quantiﬁed us-
ing a Fluor-S MultiImager with Quantity One software (Bio-
Rad) or ImageJ. Immunoﬂuorescence analysis was performed
as described previously (Bergman et al., 2009). False colours
were applied to greyscale images using ImageJ software. An-
tibody to APC was obtained from Abcam. For immunohisto-
chemistryanalysis,formalin-ﬁxed,parafﬁn-embeddedtissuewas
stained by the Cellular Pathology Department at Southamp-
ton General Hospital, essentially as described previously, us-
ing microwave antigen retrieval (Cutress et al., 2003). Primary
antibodies for the detection of CtBP1 and CtBP2 were E12
(1:250) and BD-16/CtBP2 (1:400) respectively, diluted in Tris-
buffered saline (10 mM Tris/HCl, pH 8.0, and 150 mM NaCl).
Optimum antibody dilutions were determined by titration us-
ing sections of breast tumour material. The speciﬁcity of E12
towards CtBP1, and not human CtBP2, was conﬁrmed using
HEK-293 cells that were transfected with pcDNA3.1CtBP2mh
plasmid (Mirnezami et al., 2003) and then ﬁxed and pro-
cessed the same way as the breast tumour material (results
not shown). Images of slides were captured using a Nikon
Eclipse E600 microscope equipped with a Nikon Coolpix
camera.
RNA analysis
RNA was extracted from cell lines and tissue samples using
RNABee (Biogenesis). For semi-quantitative RT−PCR ana-
lysis of transcripts, 0.5−2 μg of RNA was reverse transcribed
in a 20−25 μl volume using Superscript II RNAse H− re-
verse transcriptase (Invitrogen) and oligo(dT) primer. A 2 μl
portion of cDNA product was used as the target in 50 μl
of PCR reactions using GoTaq DNA polymerase (Promega).
Primers for the 5 -ends of each of the CTBP1 and CTBP2
mRNAs were: CTBP1−172F 5 -AGCTCGCACTTGCTCAA-
CA-3 ; CTBP1−419R 5 -TCCTCCCTGGTGAGAGTGAT-
3 ; CTBP2L 5 -GAACTATAGAGTTTGTGGAC-3 ; CTBP2R
5 -TGAGGATGTGGCAGATGGTA-3 . Primers for HIPK2
were 5 -GGCCTCACATGTGCAAGTTTTC-3  and 5 -TT-
GGTAGGTATCAAGGAGGCTC-3 ; for p14ARF encoding
mRNA they were 5 -GGTTTTCGTGGTTCACATCCCG-
CG-3  and 5 -CAGGAGCCCTCCCGGGCAGC-3 . Primers for
APC PCR have been described (Tsuchiya et al., 2000). Taq-
Man quantitative PCR for CTBP1 and CTBP2 was performed
using commercial primer/probe sets (Applied Biosystems; As-
saysonDemandHs00972288_g1andHs00949547_g1respect-
ively) using the ABI PRISM 7900HT instrument and software
(PerkinElmer Life Sciences). A standard curve was used to con-
vert threshold cycle numbers into relative transcript numbers,
which were then normalized to GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) transcript levels in the sample.
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